2011-48-5

Basic information

• Product Name: (4-METHOXYBENZYL)HYDRAZINE DIHYDROCHLORIDE
• Synonyms: (4-METHOXYBENZYL)HYDRAZINE DIHYDROCHLORIDE;USAF LA-7;(4-Methoxybenzyl)hydrazinehydrochloride;Hydrazine, [(4-Methoxyphenyl)Methyl]-, hydrochloride (1:1);[(4-methoxyphenyl)methyl]hydrazine hydrochloride;Hydrazine, p-methoxybenzyl-, hydrochloride;p-Methoxybenzylhydrazine monohydrochloride
• CAS NO: 2011-48-5
• Molecular Formula: C₈H₁₂N₂O*ClH
• Molecular Weight: 225.12
• Mol File: 2011-48-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 194-195℃ (decomposition)
• Boiling Point: 311.9°Cat760mmHg
• Flash Point: 142.5°C
• Appearance: /
• Vapor Pressure: 0.000546mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: (4-METHOXYBENZYL)HYDRAZINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHOXYBENZYL)HYDRAZINE DIHYDROCHLORIDE(2011-48-5)
• EPA Substance Registry System: (4-METHOXYBENZYL)HYDRAZINE DIHYDROCHLORIDE(2011-48-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 2011-48-5(Hazardous Substances Data)

Usage

Uses

(4-Methoxybenzyl)hydrazine Hydrochloride is used in preparation of Heterocyclic derivatives useful as SHP2 inhibitors.

InChI:InChI=1/C8H12N2O.ClH/c1-11-8-4-2-7(3-5-8)6-10-9;/h2-5,10H,6,9H2,1H3;1H

Upstream product

• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1015060-08-8 4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-d]pyrimidine-6-amine 
• 1160931-80-5 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine 
• 1292281-67-4 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-4-aminobenzamide 
• 1292281-65-2 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-4-nitrobenzamide 
• 1292282-09-7 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-4-(3-(4-(trifluoromethyl)pyrimidin-2-yl)ureido)benzamide 
• 1292282-08-6 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-5-(3-(3-methylisoxazol-5-yl)ureido)benzamide 
• 1292282-07-5 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-4-(3-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)ureido)benzamide 
• 1292282-06-4 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-4-(3-(3-morpholino-5-(trifluoromethyl)phenyl)ureido)-benzamide 
• 1292282-05-3 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-2-methyl-4-(3-(4-morpholino-3-(trifluoromethyl)phenyl)ureido)-benzamide 
• 1292282-03-1 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-(2,4-bis(trifluoromethyl)phenyl)ureido)-2-methylbenzamide 
• 1292282-02-0 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-cyclohexylureido)-2-methylbenzamide 
• 1292282-01-9 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-(4-chlorophenyl)ureido)-2-methylbenzamide 
• 1292282-00-8 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-(3-(4-chlorophenyl)ureido)-2-methylbenzamide 
• 1292281-99-2 N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-(3-chlorophenyl)ureido)-2-methylbenzamide 

Relevant articles and documents

6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE

The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.